BA
CLDX icon

BlackRock Advisors’s Celldex Therapeutics CLDX Stock Holding History

BlackRock Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$192K Buy
3,619
+145
+4% +$8.25K ﹤0.01% 2735
2016
Q3 		$211K Buy
3,474
+379
+12% +$23.6K ﹤0.01% 2659
2016
Q2 		$204K Sell
3,095
-4,021
-57% -$255K ﹤0.01% 2596
2016
Q1 		$404K Sell
7,116
-2,440
-26% -$275K ﹤0.01% 2197
2015
Q4 		$2.25M Sell
9,556
-2,131
-18% -$465K ﹤0.01% 1364
2015
Q3 		$1.85M Sell
11,687
-10,889
-48% -$3.08M ﹤0.01% 1393
2015
Q2 		$8.54M Sell
22,576
-5,510
-20% -$2.19M 0.01% 810
2015
Q1 		$11.7M Buy
28,086
+2,811
+11% +$1.01M 0.01% 738
2014
Q4 		$6.92M Buy
25,275
+672
+3% +$167K 0.01% 879
2014
Q3 		$4.78M Sell
24,603
-2,631
-10% -$573K ﹤0.01% 980
2014
Q2 		$6.67M Buy
27,234
+19,980
+275% +$4.51M 0.01% 898
2014
Q1 		$1.92M Buy
7,254
+3,428
+90% +$1.31M ﹤0.01% 1193
2013
Q4 		$1.39M Sell
3,826
-76,800
-95% -$29.6M ﹤0.01% 1323
2013
Q3 		$42.8M Sell
80,626
-41,300
-34% -$14.2M 0.04% 356
2013
Q2 		$28.5M Buy
+121,926
New +$24M 0.03% 432

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's CLDX Position: Q4 2016 in Review

BlackRock Advisors increased its Celldex Therapeutics (CLDX) stake by 4.2% in Q4 2016, buying an estimated $8.25K and bringing the position to 3,619 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

BlackRock Advisors first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $42.8M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • BlackRock Advisors held 3,619 shares of Celldex Therapeutics worth $192K as of Q4 2016.
  • BlackRock Advisors bought 145 Celldex Therapeutics shares in Q4 2016, an estimated $8.25K.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2735 holding.
  • BlackRock Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Celldex Therapeutics position peaked at $42.8M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.